The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes

OBJECTIVE: The requirement to inject current basal insulin analogs at a fixed time each day may complicate adherence and compromise glycemic control. This trial evaluated the efficacy and safety of varying the daily injection time of insulin degludec (IDeg), an ultra-long-acting basal insulin. RESEA...

Descripción completa

Detalles Bibliográficos
Autores principales: Meneghini, Luigi, Atkin, Stephen L., Gough, Stephen C.L., Raz, Itamar, Blonde, Lawrence, Shestakova, Marina, Bain, Stephen, Johansen, Thue, Begtrup, Kamilla, Birkeland, Kåre I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609505/
https://www.ncbi.nlm.nih.gov/pubmed/23340894
http://dx.doi.org/10.2337/dc12-1668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609505/
https://www.ncbi.nlm.nih.gov/pubmed/23340894
http://dx.doi.org/10.2337/dc12-1668

Ejemplares similares